Ποια είναι η τιμή για Kiromic BioPharma, Inc. (KRBP)

Η τιμή για Kiromic BioPharma, Inc. (KRBP) είναι $0.11

Ποια είναι η κεφαλαιοποίηση αγοράς για Kiromic BioPharma, Inc. (KRBP)

Η κεφαλαιοποίηση αγοράς για Kiromic BioPharma, Inc. (KRBP) είναι $3.62M

Kiromic BioPharma, Inc. (KRBP) Τιμή και Κεφαλαιοποίηση Αγοράς

Kiromic BioPharma, Inc. is a biotechnology enterprise that harnesses artificial intelligence to advance allogeneic cell therapies. The company's core mission involves crafting multi-indication T-cell treatments, specifically engineered to combat solid tumors by leveraging the innate capabilities of Gamma Delta T cells. Its developmental pipeline includes ALEXIS-ISO-1, an allogeneic gamma delta CAR-T cell therapy targeting Isomesothelin, and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy designed to address PD-L1. Supporting its research and development efforts, the company holds licensing agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, maintains a collaborative partnership for R&D with Molipharma, S.R.L., and has established a strategic alliance with Leon Office (H.K.) Ltd. Founded in 2006, the entity was initially known as Kiromic, Inc. before officially changing its name to Kiromic BioPharma, Inc. in December 2019. Its operations are headquartered in Houston, Texas.

Η τιμή για KRBP	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$165,559 $3.62M	NVDA	$5.452T	+150,507,720.84%
$136,350 $3.62M	AAPL	$4.490T	+123,954,328.88%
$126,401 $3.62M	GOOG	$4.162T	+114,910,026.31%
$111,641 $3.62M	MSFT	$3.676T	+101,491,410.12%
$86,031.91 $3.62M	AMZN	$2.833T	+78,210,724.77%

Η τιμή για KRBP

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$165,559 $3.62M